Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The value of high dose versus standard dose ara-C during induction and of IL-2 after intensive consolidation/autologous stem cell transplantation in patients (age 15-60 years) with acute myelogenous leukemia: a randomized phase II trial of the EORTC and the GIMEMA-ALWP.

Next Previous
X
Search
Trial Profile

The value of high dose versus standard dose ara-C during induction and of IL-2 after intensive consolidation/autologous stem cell transplantation in patients (age 15-60 years) with acute myelogenous leukemia: a randomized phase II trial of the EORTC and the GIMEMA-ALWP.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interleukin-2 (Primary) ; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Dec 2011 Final results for the second randomisation presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
    • 29 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Dec 2009 Biomarkers information updated

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top